[Featured Stock] Jinwon Life Sciences Soars 19%... Biden Says "Bio Also Produced in the US"
[Asia Economy Reporter Kwon Jae-hee] ZGene Life Science continues its strong performance for the second day.
As of 10:36 AM on the 14th, ZGene Life Science is trading at 12,250 KRW, up 13.43% compared to the previous trading day. During the session, it rose as much as 19.91% to 12,950 KRW before giving up some of the gains.
The previous day, ZGene Life Science had risen as much as 12.38%.
On the 12th (local time), U.S. President Joe Biden signed an executive order titled the "National Biotechnology and Biomanufacturing Initiative," focusing on domestic production in the bio sector. This initiative aims to provide various incentives to companies building domestic infrastructure in biotechnology, following semiconductors and electric vehicles.
Hot Picks Today
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- Experts Shocked by Record Numbers: "Just the Tip of the Iceberg" — The Identity Behind the 90% Dominating Teens [Chuiyakgukga]⑨
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- "Real-Life Elite League?" Ultra-Luxury Apartments Maple Xi and One Bailey Residents’ Exchange Event Draws Attention
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
ZGene Life Science owns a Contract Development and Manufacturing Organization (CDMO) in the U.S., and is expected to benefit from this legislation.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.